Leading Alzheimer’s disease expert Charles DeCarli, M.D., joins DiaGenic’s Scientific Advisory Board
DiaGenic is pleased to announce the appointment of Charles DeCarli, M.D., to its Scientific Advisory Board. Dr. DeCarli is a renowned scientist and physician whose research focuses on using advanced structural and functional brain imaging to study normal aging, mild cognitive impairment and dementia and the role of genetics, cerebrovascular and Alzheimer's disease on these processes.
Dr. DeCarli is Professor of Neurology at the University of California in Davis, California. He is the Director of the Alzheimer's Disease Center, a United States National Institutes of Health funded Alzheimer's research center. He is also Director of the Imaging of Dementia and Aging (IDeA) laboratory. He is a recipient of the J.Allyn Taylor International Prize in Medicine in recognition of his work. In addition, Dr.DeCarli is the Editor-in-Chief of Alzheimer Disease and Associated Disorders, an international journal of Alzheimer’s disease research.
“I am excited by this opportunity to assist DiaGenic in advancing the development of its very promising portfolio of diagnostic products, which, if successful, may help satisfy the fundamental unmet clinical needs of diagnosing Alzheimer’s disease and identifying patients at risk of developing Alzheimer’s disease dementia,” commented Dr. DeCarli.
“We are truly honored to have Dr. DeCarli join our Scientific Advisory Board, which is now comprised of five prominent international thought leaders in Alzheimer’s disease,” said DiaGenic’s CEO Paul de Potocki.
DiaGenic’s Scientific Advisory Board also includes Professor Bengt Winblad, theKarolinska Institute for Alzheimer’s Diseases Research Center, Professor Khalid Iqbal, New York State Institute for Basic Research i Staten Island, New York, Professor Samuel Gandy, at Mount Sinai Alzheimer’s Disease Research Center andChair at National Medical and Scientific Advisory Council for Alzheimer’s Association, and Professor Dag Aarsland, Professor of Geriatric Psychiatry, Bergen Norway andthe Karolinska Institute, Stockholm, Sweden.
For more information, contact:
Paul de Potocki, CEO at DiaGenic, telephone: +47 2324 8950
Magnus Sjögren, Chief Medical Officer at DiaGenic, telephone: +47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative diagnostic company that seeks to create value for patients, partners and investors by developing patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange.